Ieq Capital LLC bought a new stake in Encompass Health Co. (NYSE:EHC - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 44,356 shares of the company's stock, valued at approximately $4,096,000.
A number of other large investors also recently made changes to their positions in EHC. MassMutual Private Wealth & Trust FSB lifted its position in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after buying an additional 137 shares in the last quarter. Avior Wealth Management LLC bought a new position in Encompass Health in the 3rd quarter valued at $40,000. Tompkins Financial Corp purchased a new stake in shares of Encompass Health during the 4th quarter valued at $46,000. V Square Quantitative Management LLC boosted its holdings in shares of Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock worth $54,000 after buying an additional 177 shares during the last quarter. Finally, Morse Asset Management Inc bought a new position in Encompass Health during the third quarter valued at about $68,000. 97.25% of the stock is owned by institutional investors.
Encompass Health Price Performance
Shares of Encompass Health stock traded up $1.23 on Tuesday, hitting $100.11. 190,887 shares of the company traded hands, compared to its average volume of 642,040. Encompass Health Co. has a 12-month low of $73.68 and a 12-month high of $104.55. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The company has a market cap of $10.09 billion, a P/E ratio of 22.44, a P/E/G ratio of 2.31 and a beta of 0.90. The firm's 50-day simple moving average is $96.01 and its 200 day simple moving average is $96.05.
Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.
Encompass Health Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 17th. Investors of record on Tuesday, April 1st will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Tuesday, April 1st. Encompass Health's dividend payout ratio is currently 15.25%.
Insider Buying and Selling
In related news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.10% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
EHC has been the subject of a number of research reports. William Blair reissued an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. Barclays increased their price objective on Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a report on Friday, February 7th. StockNews.com upgraded Encompass Health from a "hold" rating to a "buy" rating in a research note on Saturday, February 15th. Royal Bank of Canada reiterated an "outperform" rating and set a $110.00 price target on shares of Encompass Health in a research note on Tuesday, February 11th. Finally, KeyCorp boosted their price objective on Encompass Health from $117.00 to $120.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $107.67.
Check Out Our Latest Stock Report on EHC
Encompass Health Profile
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Stories
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
